Somatic and psychiatric comorbidities of hidradenitis suppurativa in children and adolescents - 16/08/18
Abstract |
Background |
Hidradenitis suppurativa (HS) is associated with various somatic and psychiatric comorbidities. Data regarding comorbidities in young patients with HS are sparse.
Objective |
We analyzed both somatic and psychiatric comorbidities in young patients in a nationwide HS cohort.
Methods |
In this retrospective case-control study, data from cases of HS in young (age 5 to <18 years) patients and age-matched controls with benign melanocytic nevi were collected from the Finnish Care Register for Health Care. The prevalence of preselected comorbidities was compared between the HS and control groups.
Results |
A total of 153 HS cases were found in the specified age group. Of these, 34.0% had at least 1 somatic comorbidity compared with 4.9% of the controls. At least 1 of the preselected psychiatric diagnoses was present before the age of 18 years in 15.7% of case patients with HS compared with in 5.6% of the controls. By the age of 23 years, 23.5% of the patients with HS and 8.7% of the controls had at least 1 identified psychiatric comorbidity.
Limitations |
Despite this being one of the largest HS cohorts ever studied, the number of young patients with HS was relatively low. Because this was a registry-based study, it was not possible to verify the accuracy of the International Classification of Diseases codes.
Conclusion |
Physicians should monitor young patients with HS for both somatic and psychiatric comorbidities.
Le texte complet de cet article est disponible en PDF.Key words : acne inversa, comorbidities, melanocytic nevi, mental disorder, pediatric
Abbreviations used : HS, IBD, ICD-9, ICD-10, yHS
Plan
| Funding sources: None. |
|
| Disclosure: Dr Tiri has received educational grants from Novartis, Abbvie, LeoPharma, MSD, GaldermaNordic, Pfizer, Meda, and Janssen-Cilag; has received a research grant from Orion Pharma; and sits on the Advisory Board of Roche. Dr Timonen has received an honorarium from Merck for speaking. Dr Tasanen has received educational grants from Novartis and Pfizer and honoraria from Novartis, Abbvie, Janssen-Cilag, Sanofi, and Lilly for consulting and/or speaking. Dr Huilaja has received educational grants from Janssen-Cilag, Novartis, AbbVie, and LeoPharma; has received honoraria from Novartis and UCB Pharma for consulting and/or speaking; and is an investigator for Abbvie. Mr Jokelainen has no conflicts of interest to disclose. |
|
| Reprints not available from the authors. |
Vol 79 - N° 3
P. 514-519 - septembre 2018 Retour au numéro
Article précédent
- Assessing the safety of superficial chemical peels in darker skin: A retrospective study
- Shalini Vemula, Mayra B.C. Maymone, Eric A. Secemsky, Raphael Widjajahakim, Nicole M. Patzelt, Dana Saade, Neelam A. Vashi
- Surgical site identification with personal digital device: A prospective pilot study
- Leon Chen, Adam M. Parsons, Alexander B. Aria, Ana M. Ciurea, Anisha B. Patel, Christopher Chan, John R. Griffin, Tri H. Nguyen, Michael R. Migden
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?